Choice of antihypertensive drug in the diabetic patient CME

MedGenMed Medscape General Medicine

Volumn 7, Issue 2, 2005, Pages

  Ong, H T ^b   Cheah, J S ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b HT Ong Heart Clinic   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE DERIVATIVE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FASINOPRIL; FELODIPINE; GENERIC DRUG; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NEW DRUG; NIFEDIPINE; PLACEBO; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNCLASSIFIED DRUG; VALSARTAN; VERAPAMIL;

ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BIOEQUIVALENCE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIABETIC HYPERTENSION; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DRUG CHOICE; DRUG POTENCY; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; STROKE; SYSTEMATIC REVIEW; TREATMENT PLANNING; UNITED KINGDOM;

EID: 25144496523     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Guerrero-Romero JF, Alvarado-Ruiz R, Rodriguez-Moran M. Accumulated probability of hypertension in diabetes and of diabetes in hypertension. Rev Invest Clin. 1998;50:281-285.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior history of myocardial infarction. N Engl J Med. 1998;339:229-234.
3. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
4. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
5. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
6. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2002;23:B54-B64.
7. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-419.
8. Chobanian AV, Bakris GL, Black HR, et al; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-2572.
9. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
10. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organisation (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-1992.
11. Arauz-Pacheco C, Parrott MA, Raskin P; American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26:S80-S82.
12. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317:713-720.
13. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
14. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002;4:393-504.
15. Williams B. Drug treatment for hypertension: most patients will need a treatment cocktail - including a thiazide diuretic. BMJ. 2003;326:61-62.
16. Moser M. Results of ALLHAT. Is this the final answer regarding initial anti-hypertensive drug therapy? Arch Intern Med. 2003;163:1269-1273.
17. Appel LJ. The verdict from ALLHAT - thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002;288:3039-3042.
18. Davis BR, Furberg CD, Wright JT Jr, Cutler JA, Whelton P. ALLHAT: setting the record straight. Ann Intern Med. 2004;141:39-46.
19. Salvetti A, Ghiadoni L. Guidelines for antihypertensive treatment: an update after the ALLHAT study. J Am Soc Nephrol. 2004;15:S51-S54.
20. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276:1886-1892.
21. Gress TW, Neito FJ, Shahar E, Wofford MR, Brancati FL; Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. New Engl J Med. 2000;342:905-912.
22. Hasson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
23. Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens. 2000;18:1671-1675.
24. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-372.
25. Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or co-amiloride in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension. 2003;41:431-436.
26. Hansson L, Hedner T, Lund-Johansen P, et al; NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) Study. Lancet. 2000;356:359-365.
27. Black HR, Elliott WJ, Grandits G, et al; CONVINCE Research Group. Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular End points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
28. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
29. Kjeldsen SE, Julius S, Brunner H, et al; VALUE Trial Group. Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE Trial. Blood Press. 2001;10:83-91.
30. Julius S, Kjeldsen SE, Weber M, et al; VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022-2031.
31. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049-2051.
32. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet. 2003;362:1527-1535.
33. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-1076.
34. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. A network meta-analysis. JAMA. 2003;289:2534-2544.
35. Williams B. Treating hypertension: it is not how you start but where you end that matters. J Hypertens. 2003;21:455-457.
36. Hansson L, Lindholm LH, Niskanen L, et al. Effect of ACE inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP). Lancet. 1999;353:611-616.
37. Niskanen L, Hedner T, Hasson L, Lanke J, Niklason A; CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker based treatment regime: a subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24:2091-2096.
38. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with noninsulin dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
39. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fasinopril versus Amlodipine Cardiovascular Events Randomised Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
40. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
41. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
42. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-2068.
43. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
44. Beri T, Hunsicker LG, Lewis JB, et al; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138:542-549.
45. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
46. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med. 2001;345:910-912.
47. Dahlof B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
48. Lindholm LH, Ibsen H, Dahlof B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:1004-1010.
49. Siebenhofer A, Plank J, Horvath K, et al. Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials. Diabet Med. 2004;21:18-25.
50. Marshall SM. Inhibition of the rennin-angiotensin system: added value in reducing cardiovascular and renal risk? Diabet Med. 2004;21:1-3.
51. Pitt B, Byington RP, Furberg CD, et al; PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510.
52. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001;103:1721-1726.
53. Nissen SE, Tuzcu EM, Libby P; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomised controlled trial. JAMA. 2004;292:2217-2226.
54. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-1737.
55. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;372:685-691.
56. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2006.
57. Messerli FH, Grossman E, Lever AF. Do thiazide diuretics confer specific protection against strokes? Arch Intern Med. 2003;163:2557-2560.
58. Ong HT. The JNC 7 hypertension guidelines. JAMA. 2003;290:1312.
59. Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control. Main results of the Premier Clinical trial. JAMA. 2003;289:2083-2093.
60. Gregg EW, Gerzoff RB, Caspersen CJ, Williamson DF, Narayan V. Relationship of walking to mortality among US adults with diabetes. Arch Intern Med. 2003;163:1440-1447.